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Abstract: Several studies have demonstrated that polyphenol-enriched diets may have beneficial
effects against the development of degenerative diseases, including atherosclerosis and disorders
affecting the central nervous system. This activity has been associated not only with antioxidant
and anti-inflammatory properties, but also with additional mechanisms, such as the modulation of
lipid metabolism and gut microbiota function. However, long-term studies on humans provided
controversial results, making the prediction of polyphenol impact on health uncertain. The aim
of this review is to provide an overview and critical analysis of the literature related to the effects
of the principal dietary polyphenols on cardiovascular and neurodegenerative disorders. We
critically considered and meta-analyzed randomized controlled clinical trials involving subjects
taking polyphenol-based supplements. Although some polyphenols might improve specific markers
of cardiovascular risk and cognitive status, many inconsistent data are present in literature. Therefore,
definitive recommendations for the use of these compounds in the prevention of cardiovascular
disease and cognitive decline are currently not applicable. Once pivotal aspects for the definition of
polyphenol bioactivity, such as the characterization of pharmacokinetics and safety, are addressed, it
will be possible to have a clear picture of the realistic potential of polyphenols for disease prevention.
Keywords: polyphenols; prevention; cardiovascular disease; neurodegenerative disease; cognitive
decline; meta-analysis; blood pressure; flow mediated dilation; low density lipoproteins; memory
1. Introduction
Interest in the health effects of polyphenols has exponentially increased in recent years. Since the
80s, more than 80,000 studies have been published in PubMed, reporting multiple effects on a broad
range of diseases [1]. However, most of this evidence was derived from in vitro or animal studies [2],
while human trials that evaluate long-term effects of polyphenols are particularly scant. Moreover, no
studies with hard clinical end points have been conducted so far [3]. The main limitations of current
published studies include inaccuracy in the selection of tested concentrations. In fact, much higher
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amounts of compounds than those found in dietary sources are often analyzed. In addition, the lack of
information on pharmacokinetics (absorption and metabolism) may cause the choice of compounds
that are different from those actually bioavailable. In addition, the studies aimed at identifying cellular
targets involved in the beneficial effects of dietary polyphenols challenge the translatability of these
data. In fact, polyphenols have low bioavailability, related to the appearance in food as glycosylated
compounds with a very limited intestinal absorption. However, once in the colon, enzymatic cleavage
by the microbiota releases aglycon, which could undergo absorption or additional metabolism [4].
Thus, while most studies demonstrating polyphenol mechanisms have been carried out in cultured
cells, effective concentrations and effective bioactive compounds are often not tested, challenging the
physiological relevance of these observations. As a consequence, a lot of data resulting from published
reports have little relevance in real life, with the exception of those describing beneficial effects of
polyphenols from cocoa and olive oil [5].
The health effects of polyphenols for the prevention of several disturbances ranging from cancer to
metabolic syndrome, diabetes, non-alcoholic liver disease and periodontal disease have been reported.
In the present review, we critically analyzed the literature concerning polyphenol activity on human
cardiovascular and neurodegenerative diseases. We focused on cardiovascular and neurodegenerative
diseases, whose high incidence in the world represents an increasing cause of mortality, morbidity,
and disability. We selected studies on humans taking polyphenol-enriched dietary supplements for a
preventive purpose, avoiding those based on dietary approach. Although this methodological strategy
diverges from real life, the choice to focus on determined groups of polyphenols allows us to more
accurately evaluate their biological effects, without the confounding presence of other bioactive food
components and food matrices.
2. Polyphenol Effects on Cardiovascular Disease (CVD)
2.1. Impact of Polyphenols on Cardiovascular Disease in Humans
Globally, CVD is the major cause of morbidity and mortality, accounting for 32% of all causes
and for 44% of all non-communicable disease deaths. Of these deaths, 85% are due to ischemic
heart disease and stroke [6]. In the last 18 years, the risk of dying from cardiovascular disease
or other non-communicable diseases showed a slight, but constant decrease. This trend could be
caused by the implementation of several preventive measures, including actions to reduce key risk
factors such as unhealthy diet and alcohol consumption, physical inactivity, tobacco use, and constant
exposure to air pollution [7]. The pharmacological treatment of CVD has also greatly improved
life expectancy and quality, in either primary or secondary prevention, but side-effects and limited
adherence to treatments have often dampened drug effectiveness. In addition to pharmacological
therapy, dietary supplements, functional foods and nutraceutical products are being increasingly used
for cardiovascular health, despite the lack of high-quality human trials evaluating the efficacy of such
additional interventions [8,9]. Based on the recent recommendations for high-quality polyphenol
research [10] and with the aim to provide a critical review of the recent evidence in the cardiovascular
field, we herein focused exclusively on intervention studies, conducted in primary prevention, and in
which polyphenols were taken as nutraceuticals or other titrated formulations. Two excellent reviews
extensively treated the impact of common polyphenol-based nutraceuticals and dietary products
on cardiovascular health [2,3]; readers are invited to refer to them for a comprehensive reading. In
the present work, only trials evaluating the effects of the administration of polyphenol-enriched
extracts or isolated compounds were considered, while those contemplating polyphenol-rich food
consumption, such as tea, coffee, chocolate or fruit, in any formulations (e.g., whole fresh or dried
product, beverages, etc.), or multiple compound-enriched preparations, were excluded. Particular
attention was paid to relatively long (longer than two weeks) studies and those with well-defined
cardiovascular endpoints. Systematic and quantitative analysis of data from the selected studies are
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described in the meta-analysis section, while the following narrative part discusses multiple endpoints
from recent (last five years) trials.
Amongst all the investigated CVD hallmarks, hypertension, dyslipidemia, endothelial dysfunction
and systemic inflammation were the most reported in selected literature. Specific markers have been
used for evaluating cardiovascular health. Increased total or low density lipoprotein cholesterol
(LDL-C), or diminished high density lipoprotein cholesterol (HDL-C) levels, are consolidated markers of
increased cardiovascular risk and directly contribute to the atherosclerotic plaque physiopathology [11].
In addition, other proteins like apolipoprotein A–I or paraoxonase-1, which are constitutive components
of HDL particles, mainly displaying atheroprotective effects, have been inversely correlated with
cardiovascular risk. Specific markers of endothelial activation and dysfunction, causal drivers of
vascular damage, may be measured both in plasma and through minimally invasive ultrasound
techniques. For example, endothelin-1, soluble endothelial-derived adhesion molecules (sICAM-1,
sVCAM-1), asymmetric dimethylarginine, exerting pro-inflammatory actions on vascular endothelium,
as well as high-sensitive C-reactive protein (hs-CRP), tumor necrosis factor alpha (TNF-α) and
interleukin-1 beta, systemic inflammation markers, are commonly used [12,13]. Moreover, the brachial
artery flow mediated dilation (FMD) has found wide application. It is defined as the percent change
in brachial artery diameter, following to reactive hyperaemia, typically induced by a five-minutes
circulatory arrest through a supra-systolic cuff occlusion, causing NO release and vasodilation [14].
However, high heterogeneity in experimental design, study population, compounds and endpoints
evaluated, as well as the paucity of data about the biological activity of the different metabolites
hampered the possibility of clear comparisons or univocal conclusions.
A small randomized, double-blind placebo-controlled clinical trial evaluated the effects of
200 mg/day of red grape seed extract-derived oligomeric proanthocyanidin complexes for eight weeks,
on 70 mild to moderate hyperlipidemic subjects. Argani H. and colleagues [15] observed a significant
reduction of plasma total cholesterol (−14.8 mg/dL ± 19.7 vs. baseline, p = 0.001), triglycerides
(−19.4 mg/dL ± 42.4 vs. baseline, p = 0.001) and LDL-C (−13.1 mg/dL ± 20.6 vs. baseline, p = 0.002). In
the same study, anti-atherogenic components of plasma, such as apolipoprotein A–I (9.3 mg/dL ± 11.7
vs. baseline, p= 0.001), paraoxonase-1 (4.5 IU/L± 7.7 vs. baseline, p= 0.03) and HDL-C (2.1 mg/dL ± 3.7
vs. baseline, not significant) increased as a consequence of treatment.
In another study, 70 subjects were randomized to receive 162 mg/day of quercetin from onion peel
extract or placebo in a double-blinded, placebo-controlled cross-over trial with six-week treatment
periods separated by a six-week washout period [16]. This study is of particular interest because
subjects were also controlled for plasma concentrations of quercetin, its monomethylated derivatives
tamarixetin (4′-O-methyl quercetin), isorhamnetin (3′-O-methyl quercetin) and the dehydroxylated
quercetin metabolite kaempferol. In the subgroup of the hypertensive subjects, quercetin significantly
decreased systolic blood pressure (SBP) by −3.6 mmHg (p = 0.022) when compared with placebo (mean
treatment difference, −3.9 mmHg; p = 0.049). Notwithstanding, vasoactive biomarkers including
endothelin-1, sICAM-1, sVCAM-1, asymmetric dimethylarginine, angiotensin-converting enzyme
activity, vascular/endothelial function (evaluated by peripheral arterial tonometry, a technology to
assess the reactive hyperaemia index), parameters of oxidation, were not affected by quercetin in
the total group and in the subgroup of hypertensives. In the same cohort [17], authors did not
find any significant changes in serum concentrations of leptin and adiponectin, homeostasis model
assessment-adiponectin (HOMA-AD), glucose, insulin, homeostasis model assessment of insulin
resistance (HOMA-IR), blood biomarkers of liver and renal function, hematology, serum electrolytes,
hs-CRP and plasma TNF-α. On the contrary, a randomized double-blind, placebo-controlled study
involving 72 healthy, overweight, and obese participants, randomly assigned to receive 100 mg/day of
quercetin for 12 weeks did not find any significant difference in blood pressure between treatment and
placebo arm, nor versus baseline [18]. However, treatment was effective in ameliorating endothelial
function evaluated by percent FMD (from 12.5 ± 5.2% to 15.2 ± 6.1%; p = 0.002), and circulating
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endothelial progenitor cells counts by flow cytometry (44.2 ± 25.6% vs. 52.3 ± 18.6%; p = 0.005),
compared with the baseline values.
A randomized, double-blind, placebo-controlled crossover trial evaluated the effects of pure
(−)-epicatechin (100 mg/day) and quercetin-3-glucoside (160 mg/day) on biomarkers of endothelial
dysfunction and inflammation [19] or vascular function and cardiometabolic health [20], in a cohort of
37 apparently healthy pre-hypertensive (SBP = 125=−160 mmHg) men and women aged 40–80 years.
The first analysis showed reduced plasma levels of markers of vascular inflammation, such as soluble
endothelial-selectin or interleukin-1 beta. However, the differences were not significant in most cases.
In the second analysis, epicatechin supplementation improved fasting plasma insulin and
HOMA-IR, without affecting blood pressure, arterial stiffness, nitric oxide (NO), endothelin-1, or blood
lipid profile. Quercetin-3-glucoside supplementation had no effect on FMD, insulin resistance, or
other CVD risk factors. Although the compliance and polyphenol absorption were monitored after
four weeks of treatment by measuring plasma and urine epicatechin and quercetin concentrations, no
further analysis of metabolites was carried out. However, studying pure flavonoids instead of the
original complex matrixes may raise some important issues. In fact, if on the one hand, this approach
reduces the burden of potential confounding factors, on the other, it may exclude potential favorable
interactions with other flavonoids and compounds naturally present in original sources, like cocoa
or tea.
2.2. Mechanisms of Cardioprotection
The role of oxidative stress as a promoter of endothelial dysfunction, that in turn is a driver of early
atherosclerosis and consequent cardiovascular related disorders, is no longer in doubt and provides a
support for the anti-inflammatory and anti-oxidant strategy in the field of cardioprotection [21]. The
widely described antioxidant properties of polyphenols relies on the presence of hydroxyl groups that
can be readily oxidized to produce the corresponding O-quinones [22]. This conversion results in an
effective scavenger activity towards reactive oxygen species, which occurs through the entrapment of
free radicals into stabilized chemical complexes, thus preventing further reactions [23]. This so-called
“biochemical scavenger theory” is currently the most validated one to explain the beneficial effects
towards a broad range of non-communicable diseases, including CVD. However, it has to be noted
that, although the antioxidant capacity of polyphenols has been largely tested, the results of in vitro
tests not always translate in an increased antioxidant status in humans. This lack of consistency may
be due to high variability of the single in vitro assays, as well as to individual-related factors [24].
Beyond the inhibition of oxidative stress, polyphenols also display indirect antioxidant effects,
occurring through the activation of the transcription nuclear factor erythroid 2-related factor 2
(Nrf2). This event induces endogenous antioxidant systems and is likely to be responsible also
for polyphenol-mediated maintenance of the correct redox balance of cells, achieved through the
equilibrium of phase I and II enzyme activity [25]. The anti-inflammatory properties of polyphenols
are strictly connected with the modulation of oxidative stress and of the balance of redox cellular
homeostasis [26]. Multiple mechanisms, most of which are mediated by the inhibition of the
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB), account for polyphenol’s
anti-inflammatory activity. These compounds are able to decrease the cellular production of
pro-inflammatory mediators [27–29] and to inhibit the expression of adhesion molecules [30], thus
impairing the chemotaxis of monocytes within the inflamed tissues. Additional mechanisms accounting
for the cardioprotective action of polyphenols target lipid metabolism, whose impairment represents a
causative factor of atherosclerosis development [31]. An exhaustive appraisal of polyphenol-enriched
food capacity to beneficially modulate lipid and lipoprotein metabolism has been recently reviewed by
our group [32]. The widely reported decrease of total and LDL-C following the intake of polyphenols
is possibly related to mechanisms occurring at hepatic and intestinal level. In the former, the reduction
of cholesterol synthesis, the increase of LDL receptor expression and activity [33] and the increase
of the cholesterol transporters ATP-Binding Cassette G5/ATP-Binding Cassette G8 expression [34]
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have been described in in vivo models. In the latter, polyphenol (i.e., epigallocatechin gallate) capacity
to displace cholesterol from intestinal micelles have been associated with increased cholesterol fecal
elimination in vivo [35]. The effect on triglyceride plasma level is possibly related to the reduction of
apolipoprotein B48 and apolipoprotein B100 production in the liver and intestine, as demonstrated in
obese subjects [36], or to the interference with lipoprotein lipase expression, as evidenced in pigs [37].
The mechanisms accounting for the increase of HDL-C are limited to in vitro evidence. Among them,
the increase in apolipoprotein A–I synthesis has been reported in cultured hepatic or intestinal cells
exposed to cocoa polyphenols [38].
Polyphenols could also be able to positively affect endothelial function, whose impairment is an
established key factor for the development of atherosclerosis. This activity has been demonstrated as an
amelioration of FMD in humans, although the effective dose was significantly higher than the typical
dietary intake [39]. The mechanism accounting for improved FMD probably relies on the increase
of NO synthase activity, as suggested by in vitro [40] and human studies [41]. This NO-mediated
vasodilation, together with the influence on the renin-angiotensin system [42], is responsible for the
reduction of blood pressure, an additional cardioprotective activity of polyphenols. Interestingly, this
effect is also evident upon consumption of low, habitual amount of polyphenol-rich food [43].
Finally, polyphenols cardiovascular benefit may be ascribed to the peculiar pharmacokinetic
properties mentioned above. While these compounds mainly reach the distal tract of gastrointestinal
system unchanged, once modified by the gut microbiota, they may exert a prebiotic-like activity [44],
causing the selective growth of beneficial bacteria [45–47], together with the inhibition of harmful
strains [46–48]. This effect has been demonstrated in intervention studies, as well as in ex vivo models
of fecal fermentation, possibly accounting for the amelioration of markers of CVD.
2.3. Meta-Analysis
2.3.1. Methods
The literature search was performed evaluating both MEDLINE and Embase databases, considering
all manuscript published in English language until November 10, 2018. The following search
strategy was performed: ((polyphenol) OR flavonoids) OR polyphenolic compounds) OR isoflavone)
OR flavanol) OR phytoestrogen) OR resveratrol) AND atherosclerosis) OR cardiovascular) OR
cardiovascular disorder) OR cardiovascular health. The literature search was repeated adding
the words “administration” and “therapy” using Mesh terms. Inclusion criteria were: (i) double-blind,
randomized, controlled study design; (ii) adult patients (older than 18 years); (iii) chronic polyphenol
administration; (iv) administration of polyphenols as food supplement or isolated compounds. Thus,
both sexes were considered eligible, as well as all polyphenol compounds and route of administration.
Moreover, only treatment periods over 2 weeks were included. During data extraction, the following
endpoints were analyzed: FMD, LDL-C, HDL-C, hs-CRP and blood pressure.
The meta-analysis of the data extracted from the included studies was conducted using the
Review Manager 5.2 software (Version 5.2.4 Copenhagen: The Nordic Cochrane Centre, The Cochrane
Collaboration, 2012). Data were combined using random or fixed effect models, according to data
heterogeneity. Heterogeneity between the results of different studies was examined by inspecting the
scatter in the data points and the overlap in their confidence intervals and by performing chi-square
tests and I2 statistics. When I2 was higher than 60%, a random effect model was used since it provides
a more conservative estimate of the overall effect, especially relevant when studies were of different
design and duration. Weighted mean differences and 95% confidence intervals were estimated for
each endpoint considered. Values of p < 0.05 were considered statistically significant.
2.3.2. Results
The flow chart of literature search is depicted in Figure 1.
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Figure 1. Literature search flow chart for meta-analysis on cardiovascular outcomes.
We initially detected a total of 2,370,680 studies. Once only studies involving humans in a clinical
trial wer consider d, an am unt of 123,773 studies was selected. Among these, 43 studies were
evaluated to extract cardiovascular data. Finally, 9 studies wer xcluded (Table S1), while 34 studies
w re inclu ed in the meta-an lysis (Table 1).
SBP was reported in 16 studies, ev luating a total of 1190 subjects (606 treated with polyphenols
and 584 with placebo). The overall analysis showed a significant systolic pressure reduction after
polyphenol administration (mean difference −1.01, 95%CI: −2.04; 0.02, p = 0.005) (Figure 2).
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Table 1. Study characteristics after search for cardiovascular effects.
Study Group Control Group
Author Year Compound or Extract Duration Inclusion Criteria n Age ± SD n Age ± SD Cardiovascular Endpoint
Arazi H 2014 Green tea extract 3 weeks Hypertensive 8 46.12 ± 5.4 8 48.0 ± 7.1 Blood pressure
Argani H 2016 Red grape seed extract 8 weeks moderate hyperlipidaemia 35 47.3 ± 9.3 35 46.6 ± 8.4 HDL-C, LDL-C, apolipoprotein A-I,paraoxonase
Atteritano M 2007 Genistein 104 weeks Osteopenia 198 54.7 ± 0.25 191 54.2 ± 0.19 Lipid status, ICAM-1, VCAM-1
Aubertin-Leheudre
M 2008 Isoflavone 26 weeks Postmenopausal, obese 21 57.1 ± 5.6 18 57.7 ± 5.2 Lipid status
Botden IP 2012 Red wine polyphenols 4 weeks Healthy subjects 38 61 ± 8 20 61 ± 8 Blood pressure, aortic augmentation index,pulse wave reflection index
Brüll V 2015 Quercetin 6 weeks Overweight 68 47.4 ± 10.5 68 47.4 ± 10.5 Blood pressure, ET-1, ICAM-1, VCAM-1,hs-CRP, HDL-C, LDL-C, triglycerides
Chan YH 2008 Isoflavone 12 weeks Ischaemic stroke 50 66.8 ± 9.6 52 65.8 ± 10.3 FMD, hs-CRP, blood pressure,superoxide dismutase
Chiva-Blanch G 2013 Red wine polyphenols 4 weeks Healthy subjects 67 60 ± 8 67 60 ± 8 HDL-C, LDL-C, apolipoprotein A-I
Choi EY 2015 Onion peel extract 12 weeks Overweight 34 43.6 ± 9.1 28 42.5 ± 8.9 FMD, Endothelial progenitor cells
Colacurci N 2005 Isoflavone 26 weeks Postmenopausal 29 55.4 ± 3.7 28 54.9 ± 4 FMD, ICAM-1, VCAM-1, E-selectin
Dower JI 2015 Epicatechin 4 weeks Healthy subjects 37 66.4 ± 7.9 37 66.4 ± 7.9 Blood pressure
Egert S 2009 Quercetin 6 weeks Overweight 93 45.1 ± 10.53 93 45.1 ± 10.53 HDL-C, LDL-C, triglycerides, TNF-α
Gliemann L 2013 Resveratrol 8 weeks cardiovascular riskincreased 14 65 ± 1 13 65 ± 1
HDL-C, LDL-C, triglycerides, ICAM-1,
VCAM-1
Hale G 2002 Isoflavone 2 weeks Postmenopausal 16 56.5 ± 4.5 13 58 ± 7.2 FMD
Hallund J 2006 Isoflavone 8 weeks Postmenopausal 28 57 ± 5 28 57 ± 5 FMD, ET-1, blood pressure,
Hanson LN 2006 Isoflavone 6 weeks Postmenopausal 14 60 (60–70) 14 56 (49–70) hs-CRP
Hassellund SS 2013 Anthocyanins 4 weeks Hypertension 27 41 ± 3 27 41 ± 3 HDL-C, LDL-C, triglycerides
Howes JB 2000 Red-clover isoflavones 4 weeks Type 2 diabetes mellitus 75 58 ± 7.3 75 58 ± 7.3 HDL-C, LDL-C, triglycerides
Howes JB 2003 Red-clover isoflavones 4 weeks Type 2 diabetes mellitus 19 62 ± 2 19 62 ± 2 Blood pressure
Jayagopal V 2002 Isoflavone 12 weeks Postmenopausal, type 2diabetes mellitus 32 62.5 ± 6.8 32 62.5 ± 6.8 HDL-C, LDL-C, triglycerides
Lockyer S 2017 Phenolic-rich oliveleaf extract 12 weeks Healthy subjects 30 45.3 ± 12.7 30 45.3 ± 12.7
HDL-C, LDL-C, triglycerides,
blood pressure
Mainini G 2013 Isoflavone 12 weeks Postmenopausal 67 54.6 ± 5 61 54.6 ± 5 HDL-C, LDL-C, triglycerides,apolipoprotein A-I
Nestel P 2007 Trans-tetrahydrodaidzein 5 weeks Postmenopausal,overweight 25 57 ± 7 25 57 ± 7
Blood pressure, HDL-C,
LDL-C, triglycerides
Nogueira LP 2017 Green tea extract 4 weeks Hypertension, overweight 20 41.1 ± 8.4 20 41.1 ± 8.4 Blood pressure, HDL-C,LDL-C, triglycerides
Panahi Y 2015 Curcuminoid-piperinecombination 8 weeks Metabolic syndrome 59 44.8 ± 8.7 58 43.5 ± 9.7 hs-CRP
Pipe EA 2009 Soy protein isolate 4 weeks Type 2 diabetes mellitus 29 60.1 ± 9.6 29 60.1 ± 9.6 HDL-C, LDL-C, triglycerides,apolipoprotein A-I
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Table 1. Cont.
Study Group Control Group
Author Year Compound or Extract Duration Inclusion Criteria n Age ± SD n Age ± SD Cardiovascular Endpoint
Saarenhovi M 2017 Apple polyphenolextract 4 weeks Hypertension 13 55.6 ± 7.9 13 54.9 ± 6.4 FMD
Teede HJ 2003 Biochanin 6 weeks Healthy subjects 80 54 ± 0.7 80 54 ± 0.7 Blood pressure, FMD, arterial stiffness
Tomé-Carneiro J 2013 Resveratrol 26 weeks cardiovascular riskincreased 25 60 ± 12 25 58 ± 9
Apolipoprotein A-I, HDL-C,
LDL-C, triglycerides
Trautwein EA 2010 Black tea flavonoids 12 weeks Healthy subjects 31 50.1 ± 3.6 35 46.8 ± 7.1 HDL-C, LDL-C, triglycerides
Valls RM 2016 Oligopin 5 weeks Hypertension 21 NA 21 NA HDL-C, LDL-C, triglycerides,blood pressure
Verhoeven MO 2007 Isoflavone 12 weeks Postmenopausal 56 54.1 ± 4.6 59 53.8 ± 4.4 HDL-C, LDL-C, triglycerides,lipoprotein, hs-CRP
Weseler AR 2011 Flavanols 8 weeks Smokers 15 46 (30–58) 13 (30–60) HDL-C, LDL-C, triglycerides, hs-CRP
Xie L 2017 Berry polyphenol 12 weeks Smokers 25 32.6 ± 2.6 24 37.4 ± 3.0 HDL-C, LDL-C, triglycerides
ET-1: endothelin-1; FMD: flow mediated dilation; HDL-C: high-density lipoprotein-cholesterol; hs-CRP: high sensitivity C-reactive protein; ICAM-1: intercellular adhesion molecule-1;
LDL-C: low-density lipoprotein-cholesterol; VCAM-1: vascular cell adhesion molecule-1; TNF-α: tumor necrosis factor-α; NA: not available; SD: standard deviation.
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In the same studies, diastolic blood pressure was significantly reduced by polyphenol
administration (mean difference −1.32 mmHg, 95% CI: −2.37, −0.27 mmHg; p = 0.001) (Figure 3).
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cholesterol (HDL-C).
Similarly, LDL-C serum levels were significantly reduced after polyphenol administration (mean
difference −4.39 mg/dL, 95%CI: −7.66, −1.11 mg/dL, p = 0.009) (Figure 5).
FMD was reported in eight studies, for a total of 568 patients (289 treated with polyphenols and
279 with placebo). The polyphenol administration significantly increased FMD (mean difference 0.89%,
95% CI: 0.40, 1.38%, p < 0.001) (Figure 6).
Hs-CRP was reported in nine studies, for a total of 611 patients (303 treated with polyphenol and
308 with placebo). The polyphenol administration did not change hs-CRP plasma levels (p < 0.430)
(Figure 7).
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2002), while in some cases, the doses of oligomeric proanthocyanidin complexes (200 mg/day [15])
ranged around those achievable by diet [49].
According to the inclusion and exclusion criteria, a satisfactory number of studies contributed to
the analysis (17 for blood pressure, 21 for blood lipids and 9 for endothelial function and systemic
inflammation) and the number of subjects evaluated ranges from 500 to 2000, for each parameter
considered. However, high heterogeneity has been found, even because of the differences in the
treatment, in terms of formulation, dose, source and identity of the evaluated polyphenol. These
discrepancies hampered the possibility to carry out subgroup analysis. Notwithstanding, the overall
analysis revealed a significant effect of polyphenols in positively modulating the cardiovascular
parameters considered. Treatments lowered systolic and diastolic blood pressure, as well as plasma
levels of LDL-C, while increasing HDL-C levels and percent FMD. Interestingly, the effect on blood
pressure seems to be stronger in the diastolic than systolic one. Finally, no significant effects were
detected for hs-CRP by our meta-analysis. Although these effects are significant from a statistical point
of view, the detected differences are undoubtedly of modest size and their actual clinical benefit remains
to be established. For example, the absolute reduction in LDL-C (mean difference: −4.39 mg/dL) may
be of interest, since it has been shown that a linear relationship exists between LDL-C lowering and
the rate of major vascular events [50]. The effect on HDL-C is far more complex to evaluate. In fact,
the effect is due for about 95% to a single study [51] out of 21 total studies considered. Furthermore,
according to the most recent evidences coming from both Mendelian randomization studies and clinical
trials [52–54], increasing HDL-C in subjects with normal baseline values is not an effective approach
for cardiovascular risk reduction. The value of these results can be further corroborated by a recent
analysis, aimed at defining the appropriateness of outcome variables for cardiovascular health claims
compliant with European Community Regulation 1924/2006 [55]. Accordingly, the study provided
evidence of risk factors to be used for the substantiation of health claims in the context of CVD, such as
LDL-C and SBP, while other factors, like HDL-C or triglycerides, were not recommended.
3. Polyphenol Effects on Neurocognitive Functions
3.1. Impact of Polyphenols on Cognitive Functions in Humans
The significant advances in medicine have brought about a marked increase in lifespan over the
last years. Despite the obvious positive consequences, population aging led to a significant raise in the
onset of age-associated diseases, including neurodegenerative diseases [56]. Neurodegeneration is a
common condition shared by several disorders, such as amyotrophic lateral sclerosis, Huntington’s,
Alzheimer’s disease (AD), frontotemporal dementia, and Parkinson’s disease [57]. Their etiology is
multifactorial and still far from being fully understood. Among the several factors involved, chronic
and neuroinflammation, cellular senescence, genome instability and proteostasis dysregulation are
listed [58,59]. Notably, even exogenous factors and toxins may increase the risk of neurodegenerative
diseases onset by determining a persistent inflammatory status and oxidative stress [60,61]. Although
different in clinical presentation, all these diseases share common features and mechanisms, including
abnormal accumulation and aggregation of disease-specific proteins that lead to progressive loss
of specific neurons and synapses in distinct brain regions [61,62]. From a clinical point of view,
neurodegenerative diseases are characterized by a progressive impairment of the cognitive and/or motor
function, the former being the typical pre-clinical condition of AD and frontotemporal dementia [63].
Regarding AD, which represents the main cause of dementia worldwide (60−80%) [64], early symptoms
are represented by a progressive memory loss, a decline in cognitive functions, and behavioral signs,
including mood changes and depression [65]. The prodromal form of AD is defined as mild cognitive
impairment (MCI) and is characterized by alterations of specific cognitive domains among memory,
executive function, attention, visuospatial skills and language [66,67]. MCI subjects display a 50% risk
in five years for progression of neurocognitive disorders [68]. The current treatments to halt cognitive
decline are limited to counteract symptoms and have a positive impact on cognition and behavior
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only in a transient manner, without affecting the underlying pathology. This current scenario makes
the development of alternative strategies to prevent or slow the neurodegeneration an urgent need.
Among these approaches, the role of diet as a preventive tool for cognitive decline has been an object
of intensive research in the last years.
Many observational and intervention studies suggest a relationship between the administration
of polyphenol-rich products, such as berries, grape, cocoa and green tea, and an improvement in
cognitive performance [69–72]. However, not all studies have univocally brought positive results,
leaving the open question on the potential applications of polyphenols for cognitive health. First,
a recent meta-analysis reported no significant benefit of the Mediterranean diet, whose supplying of
polyphenol is about 1g/day [49], on incident cognitive impairment [73]. In addition, an overview of
the effect of soy isoflavones concluded that their effects on cognition may be limited and influenced
by several factors related to individual features, type of treatment, and the plant itself [74]. Similarly,
a meta-analysis of 21 clinical trials indicated that the treatment of MCI patients with Ginkgo biloba
extract brought inconsistent results on the cognitive endpoint [75].
Possible explanations for these discrepancies are the previously mentioned bioavailability issues
and the inter-individual variability of gut microbiota composition and function, so that the same
polyphenols may translate in different effects on people, depending on individual characteristics [76].
In summary, the lack of convincing results from the clinical trials and the above cited criticism make it
difficult to draw a solid conclusion on their preventive effects on cognitive status and neurodegeneration.
In this work, we performed a meta-analysis of human trials, in order to help clarify the efficacy
of polyphenols with respect to several aspects of cognitive decline. In detail, we focused on healthy
elderly or MCI subjects, and we considered the impact of polyphenols on global cognitive health, as
well as on specific cognitive domains, including memory, and verbal and executive functions.
3.2. Mechanisms of Neuroprotection
Multiple mechanisms are likely to account for polyphenol-induced prevention of age-related
neurodegeneration [77,78]. Seminal observations attributed these benefits to the well described radical
scavenging activity, allowing the reduction of brain cell damage. Even in the case of neuroprotection,
we have to acknowledge that in vitro tests do not always reflect effective antioxidant capacity in
humans, as stated above [24]. An additional antioxidant mechanism is the metal-chelating activity,
which may prevent the enzymatic production of reactive oxygen species, catalyzed by the metals
themselves [22]. This effect is likely to be responsible, at least in part, for the neuroprotective effective of
some flavonoids [79]. Recent evidence suggests that polyphenols, in particular flavonoids, may affect
specific processes involved in the onset of neurodegenerative disease. Among these, the reduction of
neuropathological proteins accumulation [80] and the improvement of synaptic plasticity [81] have
been described in animal models of neurocognitive dysfunction treated with physiological doses of
polyphenols. Strikingly, the role of polyphenols in improving brain vascular function, thus maintaining
cerebral blood flow underpinning cognitive activity, has been well established in young and old
adults [82,83].
Less consistent results are obtained in the research for polyphenol-mediated protection of
neuroinflammation. The potential anti-inflammatory mechanisms have been described in glial and
neuronal cells exposed to supraphysiological concentrations of flavonoids and some studies on
humans revealed flavonoid ability to reduce plasma levels of several inflammatory markers [84,85].
However, the anti-inflammatory potential of polyphenols remains uncertain, since these effects were not
confirmed in other small trials [86,87]. An additional mechanism explaining the neuroprotective action
of polyphenols against AD is the inhibition of cholinesterases, resulting in increased cholinergic activity
and improved cognitive performance [88]. This activity has been described for resveratrol, which
was able to reduce acetylcholinesterase in specific brain regions of diabetic rats, with a consequent
amelioration of memory impairment [89].
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The previously described inter-relationships between polyphenols and microbiota also have
relevant implication in the setting of neuroprotection. Indeed, intestinal-derived metabolites of
polyphenols have been shown to prevent amyloid oligomerization with potential protection against
neurodegenerative disorders in rats [90].
3.3. Meta-Analysis
3.3.1. Methods
The literature search was performed evaluating both MEDLINE and Embase databases, considering
all manuscript published in English-language until November 10, 2018. The following search strategy
was performed: ((polyphenol) OR flavonoids) OR polyphenolic compounds) OR Isoflavone) OR
flavanol) OR phytoestrogen) OR resveratrol) AND neurocognitive function) OR cognitive function) OR
cognition. The literature search was repeated adding the words “administration” and “therapy” using
Mesh terms. Inclusion criteria were the same described above. During data extraction, the following
endpoints were considered: Wisconsin Card Classification Test (WCST) [91], Reys Auditory Verbal
Learning Task (RAVLT) [92], Trail Making test (TMT A and B) [93], Alzheimer’s Disease Assessment
Scale-cognitive subscale (ADAS-Cog) [94], Mini-Mental State Examination (MMSE) [95] and Wechsler
Adult Intelligence Scale (WAIS) [96]. The meta-analysis of the data extracted from the included studies
was conducted as described in the Section 2.3.1.
3.3.2. Results
The literature search detected 293,093 documents. Studies evaluating animal or cellular models
were excluded and 19,907 remained for the abstract evaluation. Among these, 61 studies fulfilled
inclusion criteria and were further evaluated for data extraction. Neurocognitive endpoints considered
for the analysis were available in 21 studies, which were entered in the meta-analysis (Figure 8 and
Table 2).
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Table 2. Study characteristics after search for neurocognitive effects.
Study Group Control Group
Author Year Compound orExtract Duration Inclusion Criteria n Age ± SD n Age ± SD Neurocognitive Endpoints
Dai CX 2018 Ginkgo bilobaextract 12 weeks Depression 68 66..48 ± 4.12 68 66.82 ± 3.35 HAMD, WCST
Anton SD 2017 Resveratrol 12 weeks Healthy subjects 12 73.17 ± 2.08 10 73.3 ± 2.06
Trail Making, Digits Forward and Backward, Erikson-Flanker,
Controlled Oral Word Association, Hopkins Verbal Learning
Test-Revised, and Task Switching
Evans HM 2017 Resveratrol 14 weeks post-menopausalwomen 39 61.5 ± 1.1 40 61.5 ± 1.2
RAVLT, trail making test, visual spatial working memory,
semantic memory tests, Profile of Mood States
Lee J 2016 Grapeformulation 24 weeks
Cognitive
impairment 5 71.2 ± 2.06 5 73.2 ± 5.02
ADAS-Cog, Hopkins VLT, FAS, trail making test, WCST-64,
WAIS-IIIWATR, MMSE, HDRS, HARS, CIBIC-Plus
Gleason CE 2015 Soy isoflavones 25 weeks Healthy subjects 32 75.7 ± 7.7 33 76.8 ± 6.8 MMSE, verbal memory, Mazes, trail making test, stroop colorword test, fluency, visual memory, visual motor, GDS, POMS
Witte AV 2014 Resveratrol 26 weeks Healthy subjects 23 64.8 ± 6.8 23 63.7 ± 5.3 Auditory Verbal Learning Test, MRI
Gavrilova SI 2014 Ginkgo bilobaextract 24 weeks
Cognitive
impairment 80 65 ± 7 79 63 ± 7
CAMCOG, MMSE, Neuropsychiatric Inventory, State-Trait
Anxiety Inventory, Geriatric Depression Scale,
Trail-Making Test
Henderson VW 2012 Isoflavone-richsoy protein 120 weeks
post-menopausal
women 175 61 ± 7 175 61 ± 7
Neuropsychological battery, Wechsler Test of Adult Reading,
Center for Epidemiological Studies Depression scale (CES-D)
Kaschel R 2011 Ginkgo bilobaextract 6 weeks Healthy subjects 88 45–56 89 45–56 Memory tests
Snitz BE 2009 Ginkgo bilobaextract 312 weeks Healthy subjects 1545 79.1 ± 3.3 1524 79.1 ± 3.3 MMSE, ADASCog
Gleason CE 2009 Isoflavone-richsoy protein 24 weeks Healthy subjects 15 73.0 ± 7.9 15 74.3 ± 6.3
Buschke Selective Reminding test, VSL, Boston Naming test,
FAS, Grooved Pegboard, Stroop Color Word test, Mazes, Trail
Making Test
Stough C 2008 Bacopamonnieri extract 12 weeks Healthy subjects 33 41.6 ± 13.4 29 44.3 ± 11.3 CDR, RVIP
McCarney R 2008 Ginkgo bilobaextract 24 weeks Dementia 88 79.3 ± 7.77 88 79.7 ± 7.53 ADAS-Cog, QOL-AD
Woelk H 2007 Ginkgo bilobaextract 4 weeks Anxiety disorder 60 47.6 ± 11.7 37 46.7 ± 13 HAMA, CGI-C, EAAS
Casini ML 2006 Isoflavone-richsoy protein 24 weeks
post-menopausal
women 77 49 ± 4.3 77 50 ± 3.9 Digit Symbol Test, WAIS, HRSD
Kreijkamp-Kaspers S 2004 Isoflavone-richsoy protein 52 weeks
post-menopausal
women 88 66.5 ± 4.7 87 66.7 ± 4.8 MMSE, RAVLT, WAIS
Kanowski S 2003 Ginkgo bilobaextract 24 weeks
Degenerative
dementia 106 72 ± 10 99 72 ± 10 ADAS-Cog, MMSE, Clinical Global Impression of Change
Santos RF 2003 Ginkgo bilobaextract 32 weeks Healthy subjects 23 60–70 25 60–70
WAIS, Wechsler Memory Scale revised (WMS-R), WCST,
Toulouse-Pièron Concentrated Attention
Woo J 2003 Pueraria lobata(isoflavone) 12 weeks
post-menopausal
women 45 57.4 ± 4.6 39 57.2 ± 4.8 SF-36, HKLT, MMSE, WAIS; Trail making test
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Table 2. Cont.
Study Group Control Group
Author Year Compound orExtract Duration Inclusion Criteria n Age ± SD n Age ± SD Neurocognitive Endpoints
Kritz-Silverstein D 2003 Isoflavone-richsoy protein 24 weeks
post-menopausal
women 27 55–74 26 55–74
Trails A and B, category fluency, and logical memory
and recall
Mix JA 2002 Ginkgo bilobaextract 6 weeks Healthy subjects 131 66.97 ± 6.12 131 68.6 ± 6.96 SRT, WAIS, WCST
Solomon PR 2002 Ginkgo bilobaextract 6 weeks Healthy subjects 115 68.7 ± 4.7 108 69.9 ± 5.4 WAIS, WMS, CVLT, Boston Naming test
File SE 2001 Isoflavone-richsoy protein 10 weeks Healthy subjects 37 27.1 ± 3.2 37 23.9 ± 2.2 Stocking Cambridge Test, PASAT, WMS
Mix JA 2000 Ginkgo bilobaextract 6 weeks Healthy subjects 24 67.5 ± 9.23 24 68.65 ± 6.95 MMSE, SCWT, Trail Making Test, WMS
Le Bars PL 2000 Ginkgo bilobaextract 26 weeks
Degenerative
dementia 154 69 ± 10 155 69 ± 10
ADAS-Cog, Geriatric Evaluation by Relative’s Rating
Instrument(GERRI) and Clinical Global Impression of Change
Le Bars PL 1997 Ginkgo bilobaextract 52 weeks
Degenerative
dementia 166 69 ± 10 161 69 ± 10
ADAS-Cog, Geriatric Evaluation by Relative’s
Rating Instrument
ADL-IS: Activities of Daily Living International Scale; AOT: Auditory order threshold test; BLMD: Bond and Lader Mood Scale; CANTAB: Cambridge Neuropsychological Test Automated
Battery; DCT-G: Digit connection test–G; DMTS: Delayed Matching To Sample Test; HADS: Hospital Anxiety and Depression Scales; HKLT: Hong Kong List-Learning Test; ITVS: Test’s
increment threshold for visual stimuli; MMSE: Mini Mental State Examination; NPI: Neuropsychiatric Inventory; PASAT: Paced Auditory Serial Addition Task; POMS: profile of mood
states ; RAVLT: Rey Auditory Verbal Learning Test; SDS: self-rating depression scale including; SIS-M: subjective intensity scale-mood; SMS: Sensorimotor synchronization test; SRT:
Selective Reminding Test; SWM: spatial working memory; WMS: Weschler Memory Scale; SD: standard deviation.
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The excluded studies and reason for exclusion are reported in supplementary material (Table S2).
The ADAS-Cog score was reported in five studies, for a total of 508 patients treated and 501
controls. The overall effects did not show a significant impact of polyphenols on ADAS-Cog (p = 0.310).
However, the analysis showed a significant effect of Ginkgo biloba on ADAS-Cog, compared to the
placebo (mean difference −2.02, 95% CI −3.79; −0.26, p = 0.020). (Figure 9).
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Block design field, on the contrary, was evaluated in four studies, for a total of 3389 patients,
suggesting a significant reduction (p = 0.005), in particular when Ginkgo biloba was used (mean
difference −0.43, 95%CI: −0.73; −0.13, p = 0.005) (Figure S2).
WAIS Digit Span field was reported in five studies for a total of 308 patients and 309 controls. The
overall effect was not significantly affected by polyphenol administration (p = 0.600) (Figure 11).
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CST was reported in four studies for a total of 456 patients. The overall effect was not significantly
influenced by polyphenol administration (p = 0.070) (Figure S3). Trail making test A was used in seven
studies, for a total of 3473 patients. The polyphenol administration did not significantly improve this
score (p = 0.620) (Figure S4).
Si ilarly, trail making test B was used in eight studies, for a total number of 3503 subjects
(1765 patients and 1738 controls). The overall polyphenol effect was statistically significant ( ean
difference −1.59, 95 CI: −2.75; −0.43, p = 0.007), probably for the contribution of resveratrol, evaluated
in t o single studies ( ean difference −1.85, 95 CI: −3.14, −0.55, p = 0.005) (Figure 13).
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3.3.3. iscussion
In the current meta-analysis, we investigated polyphenol effects on different features of cognitive
functions, in order to provide an overall picture of the reported activities. As already specified, our
meta-analysis focused on intervention studies using polyphenol-containing food supplements. In
particular, the selected studies considered amounts of polyphenols-rich extract up to 480 mg, 300 mg
and 100 mg for Gingko biloba, resveratrol and soy isoflavones, respectively. These dosages provide an
amount of polyphenols that is very likely to be higher, compared to that reachable by diet [49].
The global cognitive functions, evaluated through MMSE and ADAS-Cog scores, were not
significantly improved by polyphenols. The only exception was Gingko biloba, whose intake translated
in an improve ent on the ADAs-Cog score, one of the most frequently used tests measuring the
extent of cognitive decline through the evaluation of language and memory. Our results strengthen the
observation of a previous meta-analysis of two studies in which a not statistically significant trend
towards improvement in ADAS-Cog score was observed in the Ginkgo biloba group [97]. Similarly,
among the different fields analyzed within the battery of the WAIS test, only the block design, often
thought as a prototype test for visuospatial ability, was improved by treatment with polyphenols. As
for ADAS-Cog, the most significant results were obtained with Gingko biloba extract. It has to be
noted that such positive result is driven by the results of one over the three studies analyzed [98]. Thus,
this observation requires confirmation with further studies. Nowadays, a possible explanation for the
efficacy of Gingko may be attributable to the presence of several active co pounds in the extract, such
as diterpenes, ginkgolides and a number of flavonoids [99]. All these molecules may act on multiple
sites in the central nervous system, all together contributing to attenuating cognitive decline.
By specifically analyzing the impact of polyphenols on distinct cognitive domains, we found a
significant improvement in the RAVLT score, which evaluates verbal learning and memory, although
the total number of subjects was limited. In particular, the three studies included in the meta-analysis
focused on the effect of soy isoflavones and resveratrol and all led to positive results. The observation
is consistent with two previous meta-analyses that were specifically aimed at investigating the effect of
resveratrol and soy [100,101]. However, the latter study utilized a unique score that took into account
the results of all neuro sychological tests together, while in our study we discriminated the effects
on specific cognitive domains. On the other hand, our results on resveratrol are inconsistent with
those of another recent meta-analysis, in which a beneficial impact has been demonstrated on t e
mood profile, rather than on memory a d cognition performance [102]. A possible explanation for
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these discrepancies is the selection criteria of the studies (in our case only aged or MCI patients were
included) and very high inter-individual differences on resveratrol bioavailability that may result from
poor water solubility, chemical instability and difference in hepatic and intestinal metabolism [103].
Another score that was ameliorated by polyphenols was TMT-B, which evaluates executive
functions, while no effect was observed on attention, measured by TMT-A. Notably, the analysis was
conducted on more than 3000 subjects, making this result clinically relevant. In addition, in this case,
the positive effect on the outcome is driven by resveratrol. The superior efficacy of resveratrol in our
meta-analysis is in agreement with the beneficial effect on cerebrovascular functions and cognition,
demonstrated in a recent trial on post-menopausal women [104].
The main limitation of this meta-analysis is related to the wide number of scores that have been
used across the trials to evaluate the impact of polyphenols on cognitive performances. In the effort
of analyzing the effect on individual scores, reflecting a particular feature of the cognitive domain,
we restricted the analysis to a small number of studies compared to those available in literature. To
overcome this criticism, as for cardiovascular markers, there is the necessity to identify the most
consolidated markers of neurocognitive improvement, also in order to accomplish to the requests
of the European Food Safety Authority (EFSA) for health claims on foods. In this regard, a precise
indication of which psychological test is more appropriate for evaluation of central nervous system
functions is lacking [105]. However, an ongoing project aims to answer this question in the neurological
context [55].
On the other hand, the strength of our work is the strict selection of subjects, which excluded
patients already affected by dementia, in order to specifically highlight some potential positive effects
of polyphenols in the prevention of cognitive decline. In conclusion, the results of this meta-analysis
suggest that polyphenol supplementation might improve specific measures of cognitive status. In
addition, among all compounds, stilbene resveratrol appears to be the most active. In the case of Gingko
biloba, the reported benefits could be attributed to the whole phytocomplex, where polyphenolic and
non-polyphenolic compounds are likely to play an active role.
Given the differences among the studies in terms of patient features and the low number of
analyzed studies, as well as the literature inconsistency across several trials, further research is needed
to verify whether long-term intake of either single or multiple polyphenols may be a promising strategy
for the prevention of cognitive decline in age-related diseases.
4. Discussion
The global, objective evaluation of polyphenol health effects presents several points of criticism.
One is the existence of almost 10,000 polyphenols with peculiar structures and physiological roles,
making the elucidation of their short- and long-term health effects challenging. Second, the recently
well-described role of microbiota in the metabolism of polyphenols accounts for different metabotypes,
which can differently affect physiological functions, producing high inter-individual differences in
the biological response. Third, it is hard to compare data coming from observational/epidemiological
studies with intervention trials. While in the former, the global effect is the result of the synergistic
interaction of multiple components of the diet, the latter, although limiting the burden of potential
confounding factors, may suffer from low adherence to real life conditions, where polyphenols are
consumed in small amounts throughout life.
As suggested by Mena in his recent commentary, research on polyphenols requires an urgent,
rigorous experimental approach in order to unravel their preventive potential on the development of
diseases [10]. According to this, the evaluation of pattern of consumption, metabolites in circulation,
inter-individual variations and new biological targets, needs to become pivotal aspects to be considered
in every study. As soon as these guidelines are accepted by all reasearchers, data collected in the field
of polyphenols and human health will be more realistic.
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In the present review, we critically evaluated and meta-analyzed only intervention studies using
polyphenol-containing food supplements, finding promising, but not definitive indications of the
preventive effects of some polyphenols on cardiovascular disease and cognitive decline.
We are aware of the limitations of this study: the selection of trials with food supplements prevents
considerations on the health benefits derived from a naturally polyphenol-enriched diet, where the
synergistic effects of different components may appear. On the same trail, the consumption of individual
polyphenolic compounds may not produce the same benefits observed in epidemiological studies.
In addition, data coming from studies on food supplements, where polyphenol intake is higher than
normal, could not be realistic in terms of interaction with drugs or other dietary components. When
polyphenols are consumed in drug formulations, they should be considered as nutraceuticals, whose
safety should also be addressed, especially if their bioavailability and biological activity are increased.
5. Conclusions
Although most polyphenol-based supplements in the market claim beneficial effects based only
on in vitro data, the amount and quality of rigorous randomized clinical trials has been increasing for
years. However, the long-term effects are yet to be elucidated and studies with hard clinical end points
are still lacking. Studies aiming to fully characterize polyphenols pharmacokinetics and their safety
are necessary to unravel their potential preventive role in real life.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/2/351/s1.
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Abbreviations
CVD Cardiovascular disease
LDL-C Low density lipoprotein cholesterol
HDL-C High density lipoprotein cholesterol
FMD Flow mediated dilation
NO Nitric oxide
TNF-α Tumor necrosis factor alpha
hs-CRP High-sensitive C-reactive protein
HOMA-AD Homeostasis model assessment-adiponectin
HOMA-IR Homeostasis model assessment of insulin resistance
AD Alzheimer’s disease
MCI Mild cognitive impairment
WCST Wisconsin card classification test
RAVLT Reys auditory verbal learning task
TMT Trail making test
ADAS-Cog Alzheimer’s Disease assessment scale-cognitive subscale
MMSE Mini-mental state examination
WAIS Wechsler adult intelligence scale
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